Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the ...

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...

BEIJING] China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even ...

CEO Neil Kumar outlined the company’s recent clinical progress, commercial momentum, and near-term regulatory plans during a ...

Don't follow general market sentiment when it comes to these two stocks.

TD Cowen 46th Annual Health Care Conference March 2, 2026 10:30 AM ESTCompany ParticipantsAlbert Bourla - Chairman of the Board ...

US pharma giant Pfizer has withdrawn its European application for a marketing authorization of Zumrad (sasanlimab) for the ...

NoA Health has appointed Louisa Lee as CEO, putting the former Novo Nordisk and Pfizer employee at the head of the creative agency’s push to take its business global. | NoA Health has appointed Louisa ...

Accelerator Lab Revenue -- $8.3 million, comprised of $5.3 million Simoa and $3 million Spatial, with Q4 performance exceeding expectations, especially in consumables and lab services. Academic ...

ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company" or "ParaZero"), an aerospace defense company pioneering smart, autonomous solutions for ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 2:30 PM ESTCompany ParticipantsJohn Jacobs - President, CEO ...

Insurance and health record data showed about 3% of smokers with peripheral artery disease were prescribed the smoking cessation drug, despite the significant benefits of quitting.